Protagonist Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTGX and other ETFs, options, and stocks.

About PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. 

CEO
Dinesh V. Patel
CEODinesh V. Patel
Employees
126
Employees126
Headquarters
Newark, California
HeadquartersNewark, California
Founded
2006
Founded2006
Employees
126
Employees126

PTGX Key Statistics

Market cap
5.47B
Market cap5.47B
Price-Earnings ratio
135.13
Price-Earnings ratio135.13
Dividend yield
Dividend yield
Average volume
838.95K
Average volume838.95K
High today
$85.60
High today$85.60
Low today
$81.00
Low today$81.00
Open price
$85.59
Open price$85.59
Volume
819.78K
Volume819.78K
52 Week high
$96.54
52 Week high$96.54
52 Week low
$33.70
52 Week low$33.70

Stock Snapshot

The current Protagonist Therapeutics(PTGX) stock price is $83.75, with a market capitalization of 5.47B. The stock trades at a price-to-earnings (P/E) ratio of 135.13.

On 2026-02-04, Protagonist Therapeutics(PTGX) stock traded between a low of $81.00 and a high of $85.60. Shares are currently priced at $83.75, which is +3.4% above the low and -2.2% below the high.

Protagonist Therapeutics(PTGX) shares are trading with a volume of 819.78K, against a daily average of 838.95K.

In the last year, Protagonist Therapeutics(PTGX) shares hit a 52-week high of $96.54 and a 52-week low of $33.70.

In the last year, Protagonist Therapeutics(PTGX) shares hit a 52-week high of $96.54 and a 52-week low of $33.70.

PTGX News

Simply Wall St 1h
Assessing Protagonist Therapeutics Valuation After Rusfertide NDA Filing And Rising Analyst Optimism

Protagonist Therapeutics (PTGX) is back in focus after filing a New Drug Application for rusfertide in polycythemia vera with partner Takeda, alongside fresh an...

Assessing Protagonist Therapeutics Valuation After Rusfertide NDA Filing And Rising Analyst Optimism

Analyst ratings

92%

of 13 ratings
Buy
92.3%
Hold
7.7%
Sell
0%

People also own

Based on the portfolios of people who own PTGX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.